Skip to main content
OpenTrials
Completed

NCT Number: NCT03710577

Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Wisconsin-Madison Natatorium

Madison, Wisconsin, 53706, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • greater than or equal to 18 years old and < 45 years old and
  • report being healthy.

Exclusion criteria

  • Being pregnant or planning to become pregnant,
  • currently smoking,
  • having a history of light headedness or fainting during blood draws or physical activity,
  • having a history of chest pain during physical activity,
  • having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
  • taking medications for any chronic diseases such as high blood pressure or diabetes,
  • responding 'Yes' to any of the seven questions on the Par-Q.

Treatment and study plan

Yoga

Behavioral

1 session

Quiet Rest

Behavioral

1 session

Primary outcomes

  1. Change in Plasma Concentration of N-arachidonoylethanolamine

    Time frame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

    Plasma concentration of anandamide, one effector of the endocannabinoid system

  2. Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG)

    Time frame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

    Plasma concentration of 2-AG, one effector of the endocannabinoid system

Secondary outcomes

  1. Change in Total Mood Disturbance as Measured by the Profile of Mood States

    Time frame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

    65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.

  2. Change in State Anxiety as Measured by the State-Trait Anxiety Inventory

    Time frame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

    20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.

  3. Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire

    Time frame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

    15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Oct 18, 2018
Registry last updated
Dec 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.